Accessibility Menu
Deciphera Pharmaceuticals logo

Deciphera Pharmaceuticals

(NASDAQ) DCPH

This security has been delisted. This page is retained for historical reference.

Deciphera Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 25.592024-06-10
Deciphera Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.12%USD 25.562024-06-03
1 month+0.91%USD 25.362024-05-10
3 month+59.04%USD 16.092024-03-12
Year to date+58.65%USD 16.132023-12-29
1 year+82.52%USD 14.022023-06-09
3 year-27.75%USD 35.422021-06-11
5 year+15.11%USD 22.232019-06-12
Since inception+44.99%USD 17.652017-09-28

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

DCPH Financials

Key Financial Metrics (TTM)

Gross Margin

97.72%

Operating Margin

-129.14%

Net Income Margin

-119.34%

Return on Equity

-56.29%

Return on Capital

-55.99%

Return on Assets

-41.16%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$167.98M

Operating Income

-$206.55M

EBITDA

-$195.33M

Operating Cash Flow

-$151.83M

Capital Expenditure

-$564.00K

Free Cash Flow

-$152.39M

Cash & ST Invst.

$272.53M

Total Debt

$25.02M

Deciphera Pharmaceuticals Performance Analysis

Deciphera Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 96,148,000N/A
20222022-12-31USD 134,036,00039.4%
20232023-12-31USD 163,356,00021.9%
Deciphera Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-3014.5%
Q32023-09-3013.1%
Q42023-12-3111.5%
Q12024-03-31-6.8%
Deciphera Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -5.16N/A
20222022-12-31USD -2.37-54.1%
20232023-12-31USD -2.29-3.3%
Deciphera Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22023-06-305.0%
Q32023-09-30-1.8%
Q42023-12-316.9%
Q12024-03-313.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2024YOY CHG

Revenue

$45.00M

+34.5%

Gross Profit

$41.31M

+25.4%

Gross Margin

91.81%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

355

N/A

Net Income

-$45.08M

+9.1%

EBITDA

-$47.25M

+11.3%

Quarterly Fundamentals

Name
Q1 2024YOY CHG

Total Cash

$272.53M

-31.6%

Total Debt

$25.02M

-11.7%

Accounts Receivable

$32.68M

+45.7%

Inventory

$21.10M

-17.4%

Long Term Debt

$21.45M

-14.3%

Short Term Debt

$3.57M

+8.3%

Return on Assets

-41.16%

N/A

Return on Invested Capital

-56.51%

N/A

Free Cash Flow

-$54.73M

-9.9%

Operating Cash Flow

-$54.59M

-10.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CALTCalliditas Therapeutics AB (publ)
$40.00-0.10%
DICEDICE Therapeutics, Inc.
$47.55+0.06%
EMBCEmbecta Corp.
$3.25-2.99%
PRVBProvention Bio, Inc.
$24.98+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
NUNu Holdings
$13.59-0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.